Meaoblast finally made it into Endtpoints. Yay!
See below snippet
Will you do the google and copy and paste.
Is "sub par data" material to the SP? well we take it that Novartis knows what we know then who to believe? MSB seem set to carry on with COVID-19 ARDs and a global pharma doesn't.
Perhaps the macro issue of FDA views of the manufacturing issues are at play?
Otherwise Mesoblast has had the strikingly good luck of corporate benevolence from 2 global pharmas "effectively" walking away for the benefit of shareholders to wear and share in the benefits of commercialisation.
Novartis walked due to "sub par data".
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
-0.030(2.27%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.28 | $677.6K | 524.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 87 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 43959 | 6 |
View Market Depth
| Last trade - 11.15am 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |